

TYME

to conquer advanced cancers.

2020 FACTSHEET

What Drives Us

Today **15 Million** people are living with cancer

by **2026** **20 Million**



Despite medical innovation, patients with advanced cancer need more and better treatment options

POSITIVE DATA READOUTS

ESMO GI Pancreatic: TYME-88-Panc Study demonstrating encouraging overall survival trends in patients with advanced pancreatic cancer

ESMO Prostate: TYME SM-88 Phase II Prostate Cancer Study demonstrating encouraging clinical benefit in patients with recurrent prostate cancer

AACR 2020: Presented new preclinical data supporting SM-88 mechanism of action. TYME-18 was also presented. TYME-18 demonstrates anti-cancer effect in new preclinical data.

TYMEINC.COM

twitter.com/tyme_inc

facebook.com/TYME2ConquerCancers

linkedin.com/company/tymeinc

revNov2020

Who We Are

TYME is an **emerging biotechnology** company focused on exploring **novel therapeutic approaches** designed to target cancer's unique metabolism.

TYME is advancing proprietary **Cancer Metabolism-Based Therapies (CMBTs™)** for **metastatic cancers**.

TYME To Make An Impact

Our unique science gives us the potential to have a significant influence on the current cancer landscape:

- Offering metastatic cancer patients new treatment options to extend and improve quality of life
- Developing a first-in-class oral CMBT, SM-88, showing compelling initial clinical trial results across 15 cancers
- Advancing our pipeline of CMBTs to change the standard of cancer care

Progress In Our Science Driving Growth

ADVANCING CLINICAL DEVELOPMENT WITH ADVOCACY PARTNERS

TYME-88-PANC: Enrolling Patients in TYME's SM-88 Pivotal Trial in third-line pancreatic cancer. For more details visit <https://tymesm88panctrial.com/>

PanCAN: Enrolling patients in Precision PromiseSM Pivotal Trial with oral SM-88 monotherapy in second-line metastatic pancreatic cancer. Details can be found at <https://clinicaltrials.gov/ct2/show/NCT04229004>

TYME/JAF HopES Sarcoma Trial: Enrolling patients in SM-88 Phase II Clinical Trial in Ewing's and high-risk sarcomas through collaboration with JAF and Dr. Chawla. For more details visit <http://tymesm88hopessarcomatrial.com/>

PUBLICATIONS

SM-88 Shows Promising Preclinical Antitumor Activity Across Several Cancers **OnLive**

Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: A bright future **The Lancet Oncology**

A first-in-human study of the novel metabolism-based anti-cancer agent SM-88 in subjects with advanced metastatic cancer **Investigational New Drugs**

REGULATORY

FDA granted TYME Orphan Drug Designation for SM-88 (racemetyrosine), as a potential treatment for patients with pancreatic cancer

Investment Rationale



TYMEINC.COM

twitter.com/tyme_inc

facebook.com/TYME2ConquerCancers

linkedin.com/company/tymeinc

Our Team

Steve Hoffman

Co-Founder, Chairman, and Chief Science Officer

Richie Cunningham

Chief Executive Officer


Jonathan Eckard

PhD, Chief Business Officer

Giuseppe Del Priore


MD, MPH, Chief Medical Officer

Delivering on Key Milestones Positions TYME for Long-Term Success



A Look Beyond:

Expanding Innovative Pipeline of Cancer Metabolism-Based Compounds (CMBTs™)



*Investigator-initiated trial
GA = gemcitabine/Abraxane®